scholarly journals The Effects of COVID-19 on the Placenta During Pregnancy

2021 ◽  
Vol 12 ◽  
Author(s):  
Habib Sadeghi Rad ◽  
Joan Röhl ◽  
Nataly Stylianou ◽  
Mark C. Allenby ◽  
Sajad Razavi Bazaz ◽  
...  

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. The virus primarily affects the lungs where it induces respiratory distress syndrome ranging from mild to acute, however, there is a growing body of evidence supporting its negative effects on other system organs that also carry the ACE2 receptor, such as the placenta. The majority of newborns delivered from SARS-CoV-2 positive mothers test negative following delivery, suggesting that there are protective mechanisms within the placenta. There appears to be a higher incidence of pregnancy-related complications in SARS-CoV-2 positive mothers, such as miscarriage, restricted fetal growth, or still-birth. In this review, we discuss the pathobiology of COVID-19 maternal infection and the potential adverse effects associated with viral infection, and the possibility of transplacental transmission.

2022 ◽  
Vol 71 (6) ◽  
pp. 2254-55
Author(s):  
Seema Shafiq ◽  
Asim Riaz

Dear Editor, It is indeed an honour for us to contribute towards the ongoing research regarding the latest contagion, Coronavirus disease (COVID-19) as caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leading to global pandemic with variable clinical outcomes. COVID-19 positive individuals present with a variety of signs and symptoms as sore throat, cough, fever, dyspnoea, headache, myalgia, nausea, and vomiting whereas, some develop severe acute respiratory distress syndrome with a fatality rate of about 10%.1 Possible oral findings include xerostomia, hypogeusia, and chemosensory alterations. Common routes of transmission being person-to-person via direct sneeze, cough, and droplet inhalation or by contact through mucosa of eyes, nose and saliva.


2021 ◽  
Vol 2 (1) ◽  
pp. 1-4
Author(s):  
Krisna Yuarno Phatama ◽  
Sholahuddin Rhatomy, MD ◽  
Asep Santoso ◽  
Nicolaas C. Budhiparama

At the end of 2019, we faced a new variant of the coronavirus that can cause pneumonia and acute respiratory distress syndrome-like symptoms. It started in Wuhan, Hubei Province, China, and spread quickly to the whole world.This new virus is called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can manifest as a disease called coronavirus disease 2019 (COVID-19). On March 13th, 2020 World Health Organization (WHO) declared COVID-19 as a global pandemic, and the story of frightening pandemic begin.


2020 ◽  
Vol 3 (2) ◽  
pp. 01-02
Author(s):  
C.A. García

Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) was first notified in Wuhan, China, in December 2019, and has rapidly spread worldwide, due to its high transmission rate. It has been identified as the causative agent of the now termed coronavirus disease (COVID-19), which can range from mild condition to potentially fatal respiratory distress syndrome


Author(s):  
Ishank Panchal ◽  
Sunita Vagha

SARS is a type of acute respiratory syndrome. Coronavirus 2 (SARSCoV2), highly contagious, affecting people worldwide. Coronavirus Disease 19 (COVID19) leads to a rapidly spreading respiratory distress syndrome. It has caused a global pandemic and severe health crisis in most countries. Due to its continual evolution, further research into the virus's pathogenicity and virulence mechanisms and the development of efficient therapy techniques are urgently required. The current paper summarises what is known about the virus's evolutionary and structural features to comprehend better its mutational pattern and probable role in the current pandemic. In December 2019, the Coronavirus Disease (SARSCoV2) began a destructive path toward a global pandemic in Wuhan, China. Since then, several SARS CoV2 variants have been discovered. Despite the speedy development of a COVID19 vaccine and ongoing mass vaccination efforts around the globe, the discovery of the latest SARSCoV2 variants could undermine the substantial success till now in stopping the spread of SARSCoV2.This review aims to characterize the different SARS CoV2 mutations and investigate the associated morbidity and death. Due to the virus's steady improvement, with its various unmarried nucleotide polymorphism (SNP) versions and lineages, figuring out SARS-CoV-2 infectivity is extraordinarily hard. but, similarly research into the virus's pathogenicity and virulence mechanisms, as well as the improvement of green therapy strategies, is urgent present-day The present day contribution summarises existing expertise regarding the virus's evolutionary and structural homes to clarify its mutational sample and ability function inside the ongoing pandemic.


2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Braira Wahid ◽  
Noshaba Rani ◽  
Muhammad Idrees

Abstract After wreaking havoc on a global level with a total of 5,488,825 confirmed cases and 349,095 deaths as of May 2020, severe acute respiratory syndrome coronavirus 2 is truly living up to the expectations of a 21st-century pandemic. Since the major cause of mortality is a respiratory failure from acute respiratory distress syndrome, the only present-day management option is supportive as the transmission relies solely on human-to-human contact. Patients suffering from coronavirus disease 2019 (COVID-19) should be tested for hyper inflammation to screen those for whom immunosuppression can increases chances of survival. As more and more clinical data surfaces, it suggests patients with mild or severe cytokine storms are at greater risk of failing fatally and hence these cytokine storms should be targets for treatment in salvaging COVID-19 patients.


Author(s):  
Subhashis Debnath ◽  
Runa Chakravorty ◽  
Donita Devi

In December 2019, severe acute respiratory syndrome-coronavirus-2, a novel coronavirus, initiated an outbreak of pneumonia from Wuhan in China, which rapidly spread worldwide. The outbreak was declared as “a public health emergency of international concern” by the WHO on January 30, 2020, and as a pandemic on March 11, 2020. The disease is transmitted by inhalation or contact with infected droplets and the incubation period ranges from 2 to 14 d. The symptoms are usually fever, cough, sore throat, breathlessness, fatigue, malaise among others. The disease is mild in most people; in some (usually the elderly and those with comorbidities), it may progress to pneumonia, acute respiratory distress syndrome (ARDS) and multi organ dysfunction. Many people are asymptomatic. The virus spreads faster than its two ancestors the SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), but has lower fatality.


2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Gokhan Sargın ◽  
Osman Elbek ◽  
Cem Balantekin ◽  
İbrahim Meteoglu ◽  
Nil Culhacı

Nitrofurantoin is a synthetic nitrofuran compound. It is generally used in urinary tract infections, either alone or in combination with other antibiotics. A number of adverse effects may develop in different body systems during nitrofurantoin treatment; however, concomitant pulmonary and hepatotoxicity are rare. In this paper, we present a case of acute respiratory distress syndrome and hepatotoxicity following administration of a single dose of nitrofurantoin.


2009 ◽  
Vol 83 (14) ◽  
pp. 7062-7074 ◽  
Author(s):  
Barry Rockx ◽  
Tracey Baas ◽  
Gregory A. Zornetzer ◽  
Bart Haagmans ◽  
Timothy Sheahan ◽  
...  

ABSTRACT Several respiratory viruses, including influenza virus and severe acute respiratory syndrome coronavirus (SARS-CoV), produce more severe disease in the elderly, yet the molecular mechanisms governing age-related susceptibility remain poorly studied. Advanced age was significantly associated with increased SARS-related deaths, primarily due to the onset of early- and late-stage acute respiratory distress syndrome (ARDS) and pulmonary fibrosis. Infection of aged, but not young, mice with recombinant viruses bearing spike glycoproteins derived from early human or palm civet isolates resulted in death accompanied by pathological changes associated with ARDS. In aged mice, a greater number of differentially expressed genes were observed than in young mice, whose responses were significantly delayed. Differences between lethal and nonlethal virus phenotypes in aged mice could be attributed to differences in host response kinetics rather than virus kinetics. SARS-CoV infection induced a range of interferon, cytokine, and pulmonary wound-healing genes, as well as several genes associated with the onset of ARDS. Mice that died also showed unique transcriptional profiles of immune response, apoptosis, cell cycle control, and stress. Cytokines associated with ARDS were significantly upregulated in animals experiencing lung pathology and lethal disease, while the same animals experienced downregulation of the ACE2 receptor. These data suggest that the magnitude and kinetics of a disproportionately strong host innate immune response contributed to severe respiratory stress and lethality. Although the molecular mechanisms governing ARDS pathophysiology remain unknown in aged animals, these studies reveal a strategy for dissecting the genetic pathways by which SARS-CoV infection induces changes in the host response, leading to death.


Sign in / Sign up

Export Citation Format

Share Document